Publications

Home Pages Publications

Reviews and Models

photo of scientist working with cell cultures in petri dishes
  1. Houghton, P.J., Adamson, P.C., Blaney, S., Fine, H.A., Gorlick, R., Haber, M., Helman, L., Hirschfeld, S., Hollingshead, M.G., Israel, M.A., Lock, R.B., Maris, J.M., Merlino, G., Patterson, W., Reynolds, C.P., Shannon, K., Yu, A., Yu, J., Smith, M.A. (2002). Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res 8, 3646-57. PM:12473573
  2. Kang, M.H., Smith, M.A., Morton, C.L., Keshelava, N., Houghton, P.J., Reynolds, C.P. (2011). National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56, 239-49. PM:20922763
  3. Houghton, P.J., Morton, C.L., Tucker, C., Payne, D., Favours, E., Cole, C., Gorlick, R., Kolb, E.A., Zhang, W., Lock, R., Carol, H., Tajbakhsh, M., Reynolds, C.P., Maris, J.M., Courtright, J., Keir, S.T., Friedman, H.S., Stopford, C., Zeidner, J., Wu, J., Liu, T., Billups, C.A., Khan, J., Ansher, S., Zhang, J., Smith, M.A. (2007). The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 49, 928-40. PM:17066459
  4. Whiteford, C.C., Bilke, S., Greer, B.T., Chen, Q., Braunschweig, T.A., Cenacchi, N., Wei, J.S., Smith, M.A., Houghton, P., Morton, C., Reynolds, C.P., Lock, R., Gorlick, R., Khanna, C., Thiele, C.J., Takikita, M., Catchpoole, D., Hewitt, S.M., Khan, J. (2007). Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res 67, 32-40 PM:17210681
  5. Neale, G., Su, X., Morton, C.L., Phelps, D., Gorlick, R., Lock, R.B., Reynolds, C.P., Maris, J.M., Friedman, H.S., Dome, J., Khoury, J., Triche, T.J., Seeger, R.C., Gilbertson, R., Khan, J., Smith, M.A., Houghton, P.J. (2008). Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res 14, 4572-83 PM:18628472

Papers on Testing of Specific Agents

  1. Carol, H., Lock, R., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., Smith, M.A. (2009). Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer 53, 1255-63 PM:19554570
  2. Carol, H., Morton, C.L., Gorlick, R., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Billups, C., Smith, M.A., Houghton, P.J., Lock, R.B. (2010). Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 55, 1329-37 PM:20740623
  3. Carol, H., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Reynolds, C.P., Kang, M.H., Maris, J.M., Keir, S.T., Watkins, A., Smith, M.A., Lock, R.B. (2010). Initial testing of topotecan by the pediatric preclinical testing program. Pediatr Blood Cancer 54, 707-15 PM:20017204
  4. Carol, H., Boehm, I., Reynolds, C.P., Kang, M.H., Maris, J.M., Morton, C.L., Gorlick, R., Kolb, E.A., Keir, S.T., Wu, J., Wozniak, A.E., Yang, Y., Manfredi, M., Ecsedy, J., Wang, J., Neale, G., Houghton, P.J., Smith, M.A., Lock, R.B. (2011). Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 68, 1291-304 PM:21448591
  5. Carol, H., Reynolds, C.P., Kang, M.H., Keir, S.T., Maris, J.M., Gorlick, R., Kolb, E.A., Billups, C.A., Geier, B., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R.B. (2013). Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60, 633-41 PM:22753001
  6. Carol, H., Gorlick, R., Kolb, E.A., Morton, C.L., Manesh, D.M., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wozniak, A., Hickson, I., Lyalin, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R. (2014). Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61, 245-52 PM:24038993
  7. Carol, H., Maris, J.M., Kang, M.H., Reynolds, C.P., Kolb, E.A., Gorlick, R., Keir, S.T., Wu, J., Kurmasheva, R.T., Houghton, P.J., Smith, M.A., Lock, R.B. (2014). Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer , PM:24664981
  8. Gorlick, R., Kolb, E.A., Houghton, P.J., Morton, C.L., Phelps, D., Schaiquevich, P., Stewart, C., Keir, S.T., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Wu, J., Smith, M.A. (2009). Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 53, 594-8 PM:19554571
  9. Gorlick, R., Maris, J.M., Houghton, P.J., Lock, R., Carol, H., Kurmasheva, R.T., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Billups, C.A., Smith, M.A. (2012). Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 59, 518-24 PM:22102563
  10. Gorlick, R., Kolb, E.A., Houghton, P.J., Morton, C.L., Neale, G., Keir, S.T., Carol, H., Lock, R., Phelps, D., Kang, M.H., Reynolds, C.P., Maris, J.M., Billups, C., Smith, M.A. (2012). Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer 59, 1266-74 PM:22315240
  11. Gorlick, R., Kolb, E.A., Keir, S.T., Maris, J.M., Reynolds, C.P., Kang, M.H., Carol, H., Lock, R., Billups, C.A., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2014). Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 61, 158-64 PM:23956067
  12. Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., Smith, M.A. (2008). Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 799-805 PM:17635004
  13. Houghton, P.J., Morton, C.L., Kolb, E.A., Lock, R., Carol, H., Reynolds, C.P., Keshelava, N., Maris, J.M., Keir, S.T., Wu, J., Smith, M.A. (2008). Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 37-45 PM:17420992
  14. Houghton, P.J., Morton, C.L., Gorlick, R., Lock, R.B., Carol, H., Reynolds, C.P., Kang, M.H., Maris, J.M., Keir, S.T., Kolb, E.A., Wu, J., Wozniak, A.W., Billups, C.A., Rubinstein, L., Smith, M.A. (2010). Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther 9, 101-12 PM:20053767
  15. Houghton, P.J., Morton, C.L., Gorlick, R., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wu, J., Smith, M.A. (2010). Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54, 921-6 PM:20166202
  16. Houghton, P.J., Morton, C.L., Kang, M., Reynolds, C.P., Billups, C.A., Favours, E., Payne-Turner, D., Tucker, C., Smith, M.A. (2010). Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program. Pediatr Blood Cancer 55, 1224-6 PM:20979180
  17. Houghton, P.J., Lock, R., Carol, H., Morton, C.L., Phelps, D., Gorlick, R., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wozniak, A.W., Gu, Y., Wilson, W.R., Smith, M.A. (2011). Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program. Pediatr Blood Cancer 57, 443-53 PM:21744473
  18. Houghton, P.J., Kang, M.H., Reynolds, C.P., Morton, C.L., Kolb, E.A., Gorlick, R., Keir, S.T., Carol, H., Lock, R., Maris, J.M., Billups, C.A., Smith, M.A. (2012). Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 58, 636-9 PM:21681929
  19. Houghton, P.J., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Morton, C.L., Keir, S.T., Reynolds, C.P., Kang, M.H., Phelps, D., Maris, J.M., Billups, C., Smith, M.A. (2012). Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 58, 191-9 PM:21337679
  20. Houghton, P.J., Lock, R., Carol, H., Morton, C.L., Gorlick, R., Anders, K.E., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Billups, C.A., Zhang, M.X., Madden, S.L., Teicher, B.A., Smith, M.A. (2012). Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer 58, 200-9 PM:21548007
  21. Kang, M.H., Reynolds, C.P., Houghton, P.J., Alexander, D., Morton, C.L., Kolb, E.A., Gorlick, R., Keir, S.T., Carol, H., Lock, R., Maris, J.M., Wozniak, A., Smith, M.A. (2012). Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer 59, 185-8 PM:21538821
  22. Kang, M.H., Reynolds, C.P., Maris, J.M., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Wu, J., Lyalin, D., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2014). Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatr Blood Cancer , PM:24623675
  23. Keir, S.T., Maris, J.M., Lock, R., Kolb, E.A., Gorlick, R., Carol, H., Morton, C.L., Reynolds, C.P., Kang, M.H., Watkins, A., Houghton, P.J., Smith, M.A. (2010). Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 55, 1126-33 PM:20672370
  24. Keir, S.T., Maris, J.M., Reynolds, C.P., Kang, M.H., Kolb, E.A., Gorlick, R., Lock, R., Carol, H., Morton, C.L., Wu, J., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2013). Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer 60, 783-90 PM:23335050
  25. Keshelava, N., Houghton, P.J., Morton, C.L., Lock, R.B., Carol, H., Keir, S.T., Maris, J.M., Reynolds, C.P., Gorlick, R., Kolb, E.A., Wu, J., Smith, M.A. (2009). Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 53, 505-8 PM:19418547
  26. Kolb, E.A., Gorlick, R., Houghton, P.J., Morton, C.L., Lock, R.B., Tajbakhsh, M., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., Smith, M.A. (2008). Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 1198-206 PM:17914733
  27. Kolb, E.A., Gorlick, R., Houghton, P.J., Morton, C.L., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Keir, S.T., Billups, C.A., Smith, M.A. (2008). Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 1190-7 PM:18260118
  28. Kolb, E.A., Gorlick, R., Houghton, P.J., Morton, C.L., Neale, G., Keir, S.T., Carol, H., Lock, R., Phelps, D., Kang, M.H., Reynolds, C.P., Maris, J.M., Billups, C., Smith, M.A. (2010). Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 55, 668-77 PM:20806365
  29. Kolb, E.A., Gorlick, R., Lock, R., Carol, H., Morton, C.L., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Billups, C., Smith, M.A., Houghton, P.J. (2011). Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 56, 595-603 PM:21298745
  30. Kolb, E.A., Gorlick, R., Keir, S.T., Maris, J.M., Lock, R., Carol, H., Kurmasheva, R.T., Reynolds, C.P., Kang, M.H., Wu, J., Houghton, P.J., Smith, M.A. (2012). Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a gamma-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer 58, 815-8 PM:22052798
  31. Kolb, E.A., Gorlick, R., Reynolds, C.P., Kang, M.H., Carol, H., Lock, R., Keir, S.T., Maris, J.M., Billups, C.A., Desjardins, C., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2013). Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 60, 1325-32 PM:23553917
  32. Kurmasheva, R.T., Reynolds, C.P., Kang, M.H., Allievi, C., Houghton, P.J., Smith, M.A. (2014). Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatr Blood Cancer 61, 922-4 PM:24166988
  33. Lock, R., Carol, H., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Reynolds, C.P., Maris, J.M., Keir, S.T., Wu, J., Smith, M.A. (2008). Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 1181-9 PM:18085673
  34. Lock, R.B., Carol, H., Morton, C.L., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Wozniak, A.W., Gorlick, R., Kolb, E.A., Houghton, P.J., Smith, M.A. (2012). Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer 58, 916-23 PM:21584937
  35. Lock, R.B., Carol, H., Maris, J.M., Kang, M.H., Reynolds, C.P., Kolb, E.A., Gorlick, R., Keir, S.T., Billups, C.A., Kurmasheva, R.T., Houghton, P.J., Smith, M.A. (2013). Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60, E42-E45 PM:23303741
  36. Maris, J.M., Courtright, J., Houghton, P.J., Morton, C.L., Kolb, E.A., Lock, R., Tajbakhsh, M., Reynolds, C.P., Keir, S.T., Wu, J., Smith, M.A. (2008). Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 51, 42-8 PM:18293383
  37. Maris, J.M., Courtright, J., Houghton, P.J., Morton, C.L., Gorlick, R., Kolb, E.A., Lock, R., Tajbakhsh, M., Reynolds, C.P., Keir, S.T., Wu, J., Smith, M.A. (2008). Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 581-7 PM:17457854
  38. Maris, J.M., Morton, C.L., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Reynolds, C.P., Kang, M.H., Wu, J., Smith, M.A., Houghton, P.J. (2010). Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55, 26-34 PM:20108338
  39. Morton, C.L., Houghton, P.J., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Reynolds, C.P., Kang, M.H., Maris, J.M., Billups, C., Smith, M.A. (2009). Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer 53, 509-12 PM:19418543
  40. Morton, C.L., Houghton, P.J., Kolb, E.A., Gorlick, R., Reynolds, C.P., Kang, M.H., Maris, J.M., Keir, S.T., Wu, J., Smith, M.A. (2010). Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer 55, 295-303 PM:20582972
  41. Reynolds, C.P., Kang, M.H., Keir, S.T., Gorlick, R., Kolb, E.A., Lock, R., Maris, J.M., Carol, H., Morton, C.L., Billups, C.A., Smith, M.A., Houghton, P.J. (2011). Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatr Blood Cancer 57, 606-11 PM:21360651
  42. Reynolds, C.P., Kang, M.H., Carol, H., Lock, R., Gorlick, R., Kolb, E.A., Kurmasheva, R.T., Keir, S.T., Maris, J.M., Billups, C.A., Houghton, P.J., Smith, M.A. (2013). Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer 60, 791-8 PM:23002019
  43. Smith, M.A., Morton, C.L., Phelps, D.A., Kolb, E.A., Lock, R., Carol, H., Reynolds, C.P., Maris, J.M., Keir, S.T., Wu, J., Houghton, P.J. (2008). Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer 51, 34-41 PM:18260120
  44. Smith, M.A., Morton, C.L., Kolb, E.A., Gorlick, R., Keir, S.T., Carol, H., Lock, R., Kang, M.H., Reynolds, C.P., Maris, J.M., Watkins, A.E., Houghton, P.J. (2010). Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer 54, 307-10 PM:19856388
  45. Smith, M.A., Maris, J.M., Lock, R., Kolb, E.A., Gorlick, R., Keir, S.T., Carol, H., Morton, C.L., Reynolds, C.P., Kang, M.H., Houghton, P.J. (2011). Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer 57, 268-74 PM:21360650
  46. Smith, M.A., Kang, M.H., Reynolds, C.P., Kurmasheva, R.T., Alexander, D., Billups, C.A., Toretsky, J.A., Houghton, P.J. (2012). Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer 59, 753-5 PM:22315235
  47. Smith, M.A., Maris, J.M., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Keir, S.T., Reynolds, C.P., Kang, M.H., Morton, C.L., Wu, J., Smith, P.G., Yu, J., Houghton, P.J. (2012). Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer 59, 246-53 PM:22012946
  48. Smith, M.A., Gorlick, R., Kolb, E.A., Lock, R., Carol, H., Maris, J.M., Keir, S.T., Morton, C.L., Reynolds, C.P., Kang, M.H., Arts, J., Bashir, T., Janicot, M., Kurmasheva, R.T., Houghton, P.J. (2012). Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer 59, 329-32 PM:21922647
  49. Tajbakhsh, M., Houghton, P.J., Morton, C.L., Kolb, E.A., Gorlick, R., Maris, J.M., Keir, S.T., Wu, J., Reynolds, C.P., Smith, M.A., Lock, R.B. (2008). Initial testing of cisplatin by the pediatric preclinical testing program. Pediatr Blood Cancer 50, 992-1000 PM:17554786
  50. Wood, A.C., Maris, J.M., Gorlick, R., Kolb, E.A., Keir, S.T., Reynolds, C.P., Kang, M.H., Wu, J., Kurmasheva, R.T., Whiteman, K., Houghton, P.J., Smith, M.A. (2013). Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer 60, 1860-7 PM:23798344